Back to Journals » Drug Design, Development and Therapy » Volume 5

Update on role of agalsidase alfa in management of Fabry disease

Authors Ramaswami U

Published 14 March 2011 Volume 2011:5 Pages 155—173

DOI https://doi.org/10.2147/DDDT.S11985

Review by Single-blind

Peer reviewer comments 3


Uma Ramaswami
Paediatric Metabolic Unit, Cambridge University Hospitals, Cambridge, UK

Abstract: Fabry disease (FD) is an X-linked lysosomal storage disorder that affects both men and women. The manifestations of this heterogeneous disease are multisystemic and progressive. Prior to the development of enzyme replacement therapy, the management and treatment for Fabry disease was largely nonspecific and supportive. Because enzyme replacement therapy became commercially available in 2001, a variety of clinical benefits in Fabry patients have been consistently reported, including improved renal pathology and cardiac function, and reduced severity of neuropathic pain and improved pain-related quality of life. This update focuses on published data on the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa, and gives a brief overview on some of the outstanding management issues in the treatment of this complex disease.

Keywords: enzyme replacement therapy, Fabry disease, agalsidase alfa

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]